1357348-22-1

Usage

Uses

Used in Pharmaceutical Industry:
(2S)-1-Benzyl 2-Methyl 4-Hydroxypiperidine-1,2-Dicarboxylate serves as a crucial intermediate in the synthesis of various pharmaceuticals. Its unique structural attributes make it a promising candidate for the creation of new drugs and medications aimed at addressing specific medical conditions.
Safety Precautions:
As with any chemical, (2S)-1-Benzyl 2-Methyl 4-Hydroxypiperidine-1,2-Dicarboxylate should be handled with care due to its potential health hazards. Appropriate safety measures must be taken to mitigate any risks associated with its use in research and development settings.

Upstream product

• 50299-14-4 N-Acetyl-α-allylglycine 
• 403503-40-2 (2S,4S)-4-Formyloxy-piperidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 133192-44-6 methyl cis-4-hydroxy-2-piperidinecarboxylate 
• 501-53-1 benzyl chloroformate 
• 144913-66-6 4-hydroxy-2-piperidine carboxylic acid methyl ester 
• 475504-28-0 4-formyloxy-(S)-pipecolic acid methyl ester 
• 211058-80-9 methyl 4(R)-hydroxypiperidine-2(S)-carboxylate 
• 403503-26-4 (2S,4R)-4-Hydroxy-1-((S)-1-phenyl-ethyl)-piperidine-2-carboxylic acid methyl ester 
• 403503-37-7 (2S,4R)-1-benzyl 2-methyl 4-hydroxypiperidine-1,2-dicarboxylate 
• 78553-47-6 methyl (2S)-2-[N-(benzyloxycarbonyl)amino]pent-4-enoate 
• 78553-51-2 (S)-2-(benzyloxycarbonylamino)pent-4-enoic acid 
• 475504-29-1 (2R)-4-formylpipecolic acid methyl ester 
• 127515-28-0 (R)-methyl 2-[N-(benzyloxycarbonyl)amino]-4-pentenoate 
• 127474-54-8 (R)-2-(benzyloxycarbonylamino)pent-4-enoic acid 

Downstream Products

• 475504-32-6 (2R,4R)-4-hydroxypipecolic acid methyl ester 
• 845256-73-7 benzyl 4-[(tert-Butoxycarbonyl)(methyl)amino]-2-(hydroxymethyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Inhibitors of influenza viruses replication

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

PROBLEM TO BE SOLVED: To provide inhibitors of influenza virus replication. SOLUTION: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient comprise administering to the biological sample or patient an effective amount of a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A compound is represented by structural formula (IA) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. COPYRIGHT: (C)2015,JPO&INPIT

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

An efficient synthesis of orthogonally protected trans- and cis-4-aminopipecolic acid

A straightforward synthesis of orthogonally Nα/N γ-protected trans- and cis-4-aminopipecolic acid is reported, starting from methyl cis-4-hydroxypiperidine-2-carboxylate. The two diastereomers were synthesized with the aid of C-4 inv

Use of hydrolases for the synthesis of cyclic amino acids

The synthesis of several cyclic amino acids that have all the necessary structural features to make them ideal scaffolds for use in medicinal chemistry is described. A key step in each synthesis is the use of hydrolase enzymes to define a chiral centre. I

Chemoenzymatic synthesis of the four diastereoisomers of 4-hydroxypipecolic acid from N-acetyl-(R,S)-allylglycine: Chiral scaffolds for drug discovery

All four diastereoisomers of 4-hydroxypipecolic acid were prepared in a form conveniently protected for drug discovery applications with the use of industrially scaleable methodology. Resolution of the racemic starting material using proprietary acylases followed by an acyliminium ion cyclisation gave diastereomeric mixtures of 4-formyloxypipecolic acid, which were differentiated using an enzyme-catalysed hydrolysis. The products were separated by partition, and by following a sequence of straightforward chemical steps, the individual stereoisomers of the protected 4-hydroxypipecolates were crystallized to optical purity in 100 g quantities.

Stereoselective syntheses of 4-fluoro- and 4,4-difluoropipecolic acids

Stereoselective syntheses of 4-fluoro- and 4,4-difluoropipecolic acids starting from Z-protected 4-hydroxy- and 4-oxopipecolates via fluorodehydroxylation and fluorodeoxygenation are described.

Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid

A new series of 4-substituted pipecolic acid derivatives was prepared and incorporated into dipeptoids. The resulting products behave as moderately potent CCK-B antagonists but their constrained structure and its comparison with structurally related compounds yield valuable information about the conformational requirements for optimal recognition of the CCK-B receptor by antagonists.